StockNews.AI
LLY
StockNews.AI
2 days

Eli Lilly and Company Investors: Company Investigated by the Portnoy Law Firm

1. Portnoy Law Firm initiates investigation into potential securities fraud against LLY. 2. Investigation focused on misleading statements about Orforglipron trial results. 3. Orforglipron's weight loss results were 11.5%, below the 15% analysts expected. 4. High dropout rate of 10.3% due to side effects raises concerns. 5. Investors encouraged to join class action for recovery of losses.

3m saved
Insight
Article

FAQ

Why Bearish?

The news of a securities fraud investigation typically weighs negatively on stock prices. Historical examples include cases like Valeant Pharmaceuticals, where legal challenges led to significant stock drops.

How important is it?

The litigation and allegations can strongly affect investor confidence and market sentiment. Given LLY's significant product focus on drugs like Orforglipron, any negative news directly correlates to market movements.

Why Short Term?

Investigation news can cause immediate investor concern, impacting stock prices quickly. Similar past instances show swift reactions from investors to negative legal news.

Related Companies

NVOAMGN
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Aug. 21, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Eli Lilly and Company (“Eli Lilly” or “the Company”) (NYSE: LLY) investors that the firm has initiated an investigation into possible securities fraud and may file a class action on behalf of investors. Eli Lilly investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: info@portnoylaw.com, to discuss their legal rights, or click here to join the case. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses. The investigation is focused on whether Eli Lilly made misleading statements in regard to their expectation of results of the phase 3 trial of their oral GLP-1 weight loss pill Orforglipron. In this pivotal trial, patients who took Orforglipron experienced an average of 11.5% placebo-adjusted weight loss over 72 weeks. This result was well below the 15% projected by analysts. Furthermore, 10.3% of patients on the highest dose of Orforglipron dropped out of the trial due to side effects, compared to just 2.6% of trial participants that were on a placebo. This investigation is concerned with any potentially deceptive claims Eli Lilly may have made regarding the drug's projected trial outcomes. Please visit our website to review more information and submit your transaction information. The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes. Lesley F. Portnoy, Esq.Admitted CA, NY and TX Barslesley@portnoylaw.com310-692-8883www.portnoylaw.com Attorney Advertising

Related News